A phase III study in mazindol in patients with attention deficit hyperactivity disorder
Latest Information Update: 08 Jul 2019
At a glance
- Drugs Mazindol (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors NLS Pharma Ltd; NLS Pharmaceutics Ltd
Most Recent Events
- 27 Feb 2019 According to a NLS-I pharma media release, this drug is expected to reach the U.S. market as early as 2022, pending regulatory approval and other factors.
- 27 Feb 2019 New trial record